News
MDGL
515.34
+1.04%
5.30
Weekly Report: what happened at MDGL last week (0803-0807)?
Weekly Report · 1d ago
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Simply Wall St · 2d ago
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach
Seeking Alpha · 6d ago
Walmart downgraded, Palantir upgraded: Wall Street’s top analyst calls
TipRanks · 08/04 13:41
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 08/04 11:46
Madrigal Pharmaceuticals Price Target Announced at $605.00/Share by Wolfe Research
Dow Jones · 08/04 09:39
Madrigal Pharmaceuticals Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 08/04 09:39
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target
Benzinga · 08/04 09:29
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
TipRanks · 08/04 09:25
Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?
Simply Wall St · 08/03 16:21
Madrigal Pharmaceuticals Price Target Cut to $962.00/Share From $964.00 by Barclays
Dow Jones · 08/03 12:14
Madrigal Pharmaceuticals Is Maintained at Overweight by Barclays
Dow Jones · 08/03 12:14
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962
Benzinga · 08/03 12:05
Weekly Report: what happened at MDGL last week (0727-0731)?
Weekly Report · 08/03 10:01
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
TipRanks · 08/03 09:45
Madrigal Pharmaceuticals (MDGL) Stock Grapples With Widening Losses Despite Rezdiffra Growth
Simply Wall St · 07/31 22:24
Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)
Seeking Alpha · 07/31 14:41
Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities
TipRanks · 07/31 12:56
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
TipRanks · 07/31 10:36
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
TipRanks · 07/31 09:38
More
Webull provides a variety of real-time MDGL stock news. You can receive the latest news about Madrigal Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).